SCHEMBL4288245

SCHEMBL4288245

Nc1cccc(Nc2nccc(Oc3ccc4[nH]ccc4c3)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 2/20 0.49
SYK P43405 2/20 0.47
KDR P35968 11/20 0.46
ABL1 P00519 2/20 0.46
BCR P11274 2/20 0.46
SRC P12931 2/20 0.46
FLT1 P17948 2/20 0.45
FGFR1 P11362 1/20 0.45
FLT4 P35916 1/20 0.45
FLT3 P36888 1/20 0.45
MERTK Q12866 1/20 0.45
NTRK2 Q16620 1/20 0.45
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 1/20 0.44
CDK5R1 Q15078 1/20 0.44
EGFR P00533 1/20 0.44
PRKACA P17612 1/20 0.44
PRKACG P22612 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4281016 0.88 KDR (0.54) SYKKDRFLT1FGFR1FLT4
SCHEMBL4287689 0.87 KDR (0.50) SYKKDRABL1BCRSRC
SCHEMBL4283784 0.87 KDR (0.49) SYKKDRFLT1FGFR1FLT4
SCHEMBL4279286 0.87 KDR (0.49) SYKKDRABL1BCRFLT1
SCHEMBL4290886 0.87 KDR (0.49) SYKKDRFLT1FGFR1FLT4
SCHEMBL4284818 0.85 SYK (0.45) SYKKDRSRCFLT1FGFR1
SCHEMBL4291808 0.85 KDR (0.51) SYKKDR
SCHEMBL4279265 0.85 SYK (0.46) SYKKDRSRCFLT1FGFR1
SCHEMBL13805474 0.84 KDR (0.53) CDK5SYKKDRABL1BCR
SCHEMBL4288855 0.84 EGFR (0.42) CDK5SYKKDRABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US claimed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP claimed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO claimed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149467-A1 Tyrosine Kinase Inhibitors ABL1, MET, ERBB2 CDK5 113/4885SYK 86/4885KDR 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.